SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024511
Filing Date
2022-11-10
Accepted
2022-11-10 16:24:03
Documents
58
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q janx-20220930.htm   iXBRL 10-Q 3294136
2 EX-31.1 janx-ex31_1.htm EX-31.1 21934
3 EX-31.2 janx-ex31_2.htm EX-31.2 20648
4 EX-32.1 janx-ex32_1.htm EX-32.1 19236
  Complete submission text file 0000950170-22-024511.txt   11584771

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20220930.xsd EX-101.SCH 53131
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20220930_lab.xml EX-101.LAB 451083
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT janx-20220930_cal.xml EX-101.CAL 52310
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT janx-20220930_def.xml EX-101.DEF 205272
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20220930_pre.xml EX-101.PRE 326100
52 EXTRACTED XBRL INSTANCE DOCUMENT janx-20220930_htm.xml XML 2692150
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40475 | Film No.: 221377631
SIC: 2834 Pharmaceutical Preparations